Improvement of inflammatory bowel disease after allogeneic stem-cell transplantation

Transplantation. 2003 May 27;75(10):1745-7. doi: 10.1097/01.TP.0000062540.29757.E9.


Because causes of inflammatory bowel disease (IBD) remain obscure and a curative therapy is still lacking, the influence of stem-cell transplantation (SCT) on IBD is of major interest. We retrospectively analyzed the course of seven patients with Crohn's disease and four patients with idiopathic ulcerative colitis who underwent allogeneic SCT between July 1994 and August 2002 for acute and chronic myeloid leukemia and myelodysplastic syndrome. After a median follow-up of 34 months posttransplantation, 10 patients are alive. None of the patients showed IBD activity after SCT, except one patient with mild persistent symptoms of Crohn's disease early after transplant. Colonoscopy after complete discontinuation of prophylactic posttransplant immunosuppression revealed no pathologic findings. These observations imply that host immune dysregulation plays a central role in the perpetuation of IBD. It may be influenced by the implementation of a new allogeneic immune system resulting from the transplantation of hematopoietic stem cells.

MeSH terms

  • Acute Disease
  • Adolescent
  • Adult
  • Colitis, Ulcerative / complications
  • Colitis, Ulcerative / physiopathology
  • Crohn Disease / complications
  • Crohn Disease / physiopathology
  • Female
  • Humans
  • Inflammatory Bowel Diseases / complications*
  • Inflammatory Bowel Diseases / pathology
  • Inflammatory Bowel Diseases / physiopathology*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / complications*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / surgery*
  • Leukemia, Myeloid / complications*
  • Leukemia, Myeloid / surgery*
  • Male
  • Retrospective Studies
  • Stem Cell Transplantation*
  • Transplantation, Homologous
  • Treatment Outcome